Patents by Inventor Katherine Rendahl

Katherine Rendahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody drug conjugates
    Patent number: 10626172
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 21, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20190194315
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: June 17, 2016
    Publication date: June 27, 2019
    Applicant: Novartis AG
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Antibody Drug Conjugates
    Publication number: 20190119375
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 25, 2019
    Applicant: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • Antibody drug conjugates
    Patent number: 10005836
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20160137730
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: November 13, 2015
    Publication date: May 19, 2016
    Applicant: Novartis AG
    Inventors: Tinya ABRAMS, Steven Bruce Cohen, Jason Damiano, Clemens Dürr, Thomas Huber, Daniel Menezes, Kathy Miller, Katherine Rendahl, Jean-Michel Rene Rondeau
  • TREATMENT OF MELANOMA
    Publication number: 20100086518
    Abstract: Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture thereof may be used to prepare medicaments for treating metastatic cancer. The variable A has the values defined herein.
    Type: Application
    Filed: March 7, 2008
    Publication date: April 8, 2010
    Applicant: NOVARTIS AG
    Inventors: Carla C. Heise, Paul Hollenbach, Daniel Menezes, Nancy Pryer, Katherine Rendahl, Marion Wiesmann
  • Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
    Patent number: 6943153
    Abstract: Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
    Type: Grant
    Filed: September 20, 2000
    Date of Patent: September 13, 2005
    Assignees: The Regents of the University of California, Chiron Corporation
    Inventors: William C. Manning, Jr., Varavani J. Dwarki, Katherine Rendahl, Shangzhen Zhou, Sheldon S. Miller, Fei Wang
  • Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
    Publication number: 20020194630
    Abstract: Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 19, 2002
    Inventors: William C. Manning, Varavani J. Dwarki, Katherine Rendahl, Shangzhen Zhou, Laura H. McGee, Dana Lau, John G. Flannery, Sheldon S. Miller, Fei Wang, Adriana Di Polo